Pavmed (NSDQ:PAVM) said today that it filed a preliminary prospectus with the SEC for an offering of the rights to buy a new unit in exchange for each share of outstanding common stock.
The medical device company plans to offer the rights to purchase up to 9 million units at $2.25 apiece on May 21, valuing the offering at $20.3 million.
Get the full story at our sister site, Drug Delivery Business News.
The post Pavmed registers for $20m rights offering appeared first on MassDevice.
from MassDevice https://ift.tt/2I5KWf9
Cap comentari:
Publica un comentari a l'entrada